Spectral MD Holdings, Ltd
("Spectral MD" or the "Company")
Exercise of Options
LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces the exercise of options by certain employees of the Company (the "Employees").
The Employees have exercised options over an aggregate of 152,500 shares of common stock of US$0.001 each in the Company ("Common Stock") at various exercise prices between US$0.10 and US$0.21 per share of Common Stock. Accordingly, the Employees will be issued 152,500 shares of Common Stock in the Company.
The Company will apply for 152,500 shares of Common Stock to be admitted to trading on AIM, with admission expected to take place at 8:00 a.m. on or around 17 October 2022 ("Admission"). The shares of Common Stock will rank pari passu in all respects with existing Common Stock.
Following Admission, the total number of shares of Common Stock in issue will be 136,249,564, with one voting right per share of Common Stock. Therefore, the total number of voting rights in the Company will be 136,249,564.
Consequently, the above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Company's Certificate of Incorporation.
For further information please contact:
| Spectral MD Holdings, Ltd. | investors.spectralmd.com | |
| Wensheng Fan, Chief Executive Officer | via Walbrook PR | |
| Nils Windler, Chief Financial Officer |
| |
|
|
| |
| SP Angel Corporate Finance LLP (NOMAD and Joint Broker) | Tel: +44 (0)20 3470 0470 | |
| Stuart Gledhill/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Sales & Broking)
Stifel Nicolaus Europe Limited (Joint Broker) Charles Hoare / Ben Maddison / Nick Harland / Will Palmer-Brown |
Tel: +44 (0)20 7710 7600 | |
|
|
| |
| Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com | |
| Paul McManus / Louis Ashe-Jepson Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393 +44 (0)7407 804 654 | |
About Spectral MD:
We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.
www.spectralmd.com
info@spectralmd.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.